Montes Archimedes Acquisition (ROIV)
(Real Time Quote from BATS)
$11.53 USD
-0.10 (-0.86%)
Updated Aug 6, 2025 01:28 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Roivant Sciences Ltd. has a market cap of $7.91B, which represents its share price of $11.63 multiplied by its outstanding shares number of 679.81M. As a mid-cap company, ROIV's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ROIV 11.53 -0.10(-0.86%)
Will ROIV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar?
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Other News for ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide ...
Roivant Sciences (ROIV) Anticipated to Benefit from Brepocitinib Developments | ROIV Stock News
Roivant Sciences placed on 'Positive Catalyst Watch' at JPMorgan
What Does the Market Think About Roivant Sciences?
See How Roivant Sciences Ranks Among Analysts' Top Picks With Strong Buyback Activity